lupus and tirzepatide Glucagon‐Like Peptide‐1 Receptor Agonist Use the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Erythematosus and Lupus Nephritis - Jorge - 2026 - Arthritis & Rheumatology Lilly's Tirzepatide Cuts Heart Failure
Description
and Schaumberg, M
How to Increase Properly Never increase more than 2025% at a time
More serious side effects are rare but possible
If you are also taking insulin or a sulfonylurea, be aware that adding any incretin-based therapy may increase the risk of hypoglycaemia
Appiah JK et al
